Developer docs
API playgroundTry for free, no card

Search company profiles

Ambry Genetics

Full company profile

uuid0003qtx

Namestring
Ambry Genetics
Legal namestring
Ambry Genetics
Websiteurl
ambrygen.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Ambry Genetics is a clinical genetic diagnostics laboratory founded in 1999 and headquartered in Aliso Viejo, California, operating a CLIA-certified, CAP-accredited 65,000 sq. ft. SuperLab that has completed more than one million DNA/RNA tests across hereditary cancer, cardiology, neurology, and rare disease. Its core technology stack combines next-generation sequencing on Illumina platforms with PacBio long-read sequencing, layered with the proprietary +RNAinsight concurrent DNA/RNA testing method that identifies additional positive patients and reduces variants of uncertain significance. Supporting products include the Classifi variant classification program, the Patient for Life proactive reanalysis program, the ExomeReveal exome test with RNA analysis, and the CARE Program digital health platform that integrates with provider EMRs for automated risk screening, ordering, and result reporting.

The business generates revenue primarily through clinical genetic testing billed to insurance, with contracts covering roughly 95% of US insured lives and most patients paying $0 out of pocket; secondary streams include pharma services (companion diagnostics development, clinical trial support, real-world data) and data licensing. The go-to-market is a hybrid model: sales-led enterprise relationships with health systems (anchored by the CARE Program), healthcare provider ordering through the AmbryPort portal and paper requisitions, and channel partnerships such as AnyLabTestNow for sample collection and sponsored testing programs (AmbryLink) with biopharma companies. In February 2025, Ambry was acquired by Tempus AI for $600 million and now operates as a wholly-owned subsidiary, with Tempus reporting 23% hereditary volume growth in Q4 2025 and Ambry contributing to over 200 peer-reviewed publications that reinforce its scientific positioning. The company faces pending litigation including an Illinois GIPA class action related to genetic data transfer during the acquisition and a securities class action against Tempus citing billing practices at Ambry.

Short descriptiontext

Ambry Genetics is a clinical genetic diagnostics laboratory offering hereditary cancer, cardiovascular, neurological, and rare disease DNA/RNA testing through its CLIA-certified lab, serving healthcare providers, health systems, and pharmaceutical partners, and operating as a Tempus AI subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAliso Viejo, United States
HQ citystring
Aliso Viejo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genetic testing, hereditary cancer diagnostics, DNA RNA sequencing, exome diagnostic services, companion diagnostics
Industry4 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Genetic Testing
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Genetic Testing Services
TypeSubscription Recurring
Description

Ambry generates revenue through clinical genetic testing for hereditary cancer, cardiology, neurology, and rare diseases. Tests are billed to insurance (with majority of US health plans contracted), with 4 out of 5 patients paying $0 on average due to insurance coverage. For uninsured or those not using insurance, self-pay pricing is available.

ambrygen.com
2Pharma Services
TypeProfessional Services
Description

Ambry provides genetic testing services to pharmaceutical companies for drug development, clinical trial support and patient identification, real-world data services, and companion diagnostics development. Supports therapeutic areas including oncology, neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases.

ambrygen.com
3Data Licensing
TypeData Monetisation
Description

Ambry generates revenue through licensing its genetic data assets to pharmaceutical and research partners for drug discovery and development purposes. The company has contributed to research published in Nature Communications on variant effect analysis.

businesswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Standard insurance-covered testing (majority of patients)
ModelSubscriptionBilling cadencePer test
Notes

4 out of 5 patients pay $0 for genetic testing through insurance coverage. Ambry is contracted with most US health plans.

ambrygen.com
2Self-pay pricing for uninsured patients
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Cash pricing available for uninsured patients or those who do not want to use insurance benefits. Contact billing team directly for pricing.

ambrygen.com
3Financial Assistance Program
ModelHybridBilling cadenceAnnual
Notes

Personalized assessment of financial need considering location, household size, and income. Program available upon application review.

ambrygen.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1+RNAinsight®
Description

Concurrent DNA/RNA testing technology that analyzes functional RNA data to help detect and classify DNA variants, identifying more positive results and resolving variants of uncertain significance.

ambrygen.com
+6 more records
Core offering1 text field

Ambry Genetics operates one of the largest clinical genetic testing laboratories in the world, providing hereditary cancer, cardiovascular, neurological, and rare disease genetic testing from a 65,000 sq. ft. CLIA-certified, CAP-accredited facility in Aliso Viejo, CA. The laboratory offers proprietary paired DNA/RNA testing (+RNAinsight), exome-based testing (ExomeReveal), the Patient for Life proactive reanalysis program, the CARE Program digital health platform, companion diagnostics development, and pharma research services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 1 in 25 positive patients would have been missed without RNA data (using +RNAinsight)
+4 more records
Product overview1 text field

Ambry Genetics offers a comprehensive clinical genetic testing platform with multiple interconnected products and services. The core testing portfolio spans four main areas: Oncology (hereditary cancer panels with +RNAinsight®), Cardiology, Neurology, and Clinical Genomics (exome testing with ExomeReveal®). Key platform features include the CARE Program® for patient identification and workflow automation, Patient for Life Program™ for proactive reanalysis, Classifi® for variant classification, and AmbryPort® for online ordering. Additional services include pharma partnerships, telemedicine counseling, insurance pre-verification, and sponsored testing through AmbryLink. The company pioneered paired DNA/RNA testing with +RNAinsight® and offers the largest genetic sequencing lab in the world (SuperLab).

Product and service13 records
1Hereditary Cancer Test Menu
CategoryCore Product
Description

Clinical genetic testing panels for hereditary cancer syndromes, including BRCA1/2 testing, offered to healthcare providers for patient diagnosis, treatment planning, and risk assessment.

2Cardiology Test Menu
CategoryCore Product
Description

Hereditary cardiovascular genetic testing panels for inherited heart conditions, providing diagnostic insights for cardiomyopathies, arrhythmias, aortopathies, and familial hypercholesterolemia.

3Neurology Test Menu
CategoryCore Product
Description

Hereditary neurological genetic testing for neurodevelopmental, neuromuscular, movement, and seizure disorders, supporting diagnosis of pediatric and adult neurological conditions.

4Clinical Genomics Test Menu
CategoryCore Product
Description

Exome sequencing and rare disease testing for unresolved clinical cases, including trio-based exome testing and family variant testing to identify the genetic basis of rare conditions.

5+RNAinsight
CategoryAdd-on/Module
Description

Concurrent DNA and RNA testing add-on that analyzes both genomic and transcriptomic data to improve variant interpretation, identifying approximately 1 in 25 positive patients missed by DNA-only testing and reducing variants of uncertain significance by 6%.

6Patient for Life Program
CategoryAdd-on/Module
Description

Proactive reanalysis program that re-evaluates exome data as new scientific discoveries emerge, providing additional diagnoses for approximately 5% of initially negative patients without requiring a new sample.

7ExomeReveal
CategorySub-brand
Description

Exome sequencing combined with RNA analysis to provide enhanced diagnostic insights for rare disease cases, integrating transcriptomic data with genomic findings.

8CARE Program
CategoryPlatform
Description

Digital health solution that analyzes electronic medical record (EMR) data to identify at-risk patients who qualify for genetic testing, integrating into health system workflows to streamline patient identification, consent, and testing.

9Pharma Services
CategoryService
Description

Genetic testing and genomic research services for pharmaceutical companies supporting drug development, clinical trials, real-world data generation, and data licensing initiatives.

10Companion Diagnostics
CategoryService
Description

Development and validation of companion diagnostic tests to identify patients likely to respond to specific targeted therapies, supporting pharmaceutical partners in precision medicine programs.

11AmbryLink
CategoryService
Description

Sponsored genetic testing programs that enable pharmaceutical and biotech companies to fund no-cost genetic testing for patients meeting specific clinical criteria.

12Telemedicine Genetic Counseling
CategoryService
Description

Board-certified genetic counseling services delivered via telemedicine to support patients and providers in interpreting genetic test results and understanding implications.

13Sample Collection Kit Delivery
CategoryService
Description

Direct-to-patient and direct-to-provider shipping of sample collection kits for saliva and blood samples, supporting remote specimen collection across the United States and Canada.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Child Neurology Foundation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Ambry Genetics named Champion Level Partner of the Child Neurology Foundation, supporting the foundation's education initiatives and resources for families and healthcare professionals in pediatric neurology. The partnership aims to advance earlier diagnosis and strengthen care through evidence-based education, diagnostics, and resources.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Genome Medical, a nationwide specialty medical practice focused on genetic counseling, to provide expert genetic consultations for patients who may be at risk for common hereditary cancers. Genome Medical genetic experts and primary care MDs work with patients to determine whether genetic testing is appropriate.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with MDxHealth to increase genetic testing within the urology market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with AnyLabTestNow for local laboratory sample collection services, enabling patients to visit nearby locations for blood draws.

5PRECEDE Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with REALM IDx (parent company of Ambry Genetics) and PRECEDE Consortium to bring expertise in genetic testing, pathology, and imaging to determine who is at elevated risk for pancreatic cancer and invite high-risk individuals into state-of-the-art clinical screening programs.

ambrygen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

FCS Seek program - Arrowhead Pharmaceutical Program offers confidential genetic testing for patients with clinical history of severe hypertriglyceridemia, testing for underlying genetic causes like Familial Chylomicronemia Syndrome (FCS) and hyperlipoproteinemia.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Mission: Genome Danon Disease Genetic Testing Program - testing for patients under 40 years of age meeting select eligibility utilizing Ambry's CardioNext testing panel.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Caris is a molecular science competitor with commercial overlap with Ambry in oncology testing and an existing mutual commercial partnership. It competes for oncology hereditary and somatic testing volume.

TypeEmerging player
Description

Color offers hereditary cancer and population genetic testing with a digital-first model and employer/payer channels. It overlaps with Ambry on hereditary cancer testing but differentiates through consumer/employer distribution rather than provider referrals.

TypeRegional player
Description

Centogene focuses on rare disease diagnostics and hereditary testing primarily in Europe, the Middle East, and LatAm. It is a direct competitor in rare disease exome testing but operates in geographies where Ambry does not currently accept orders.

TypeBroad incumbent
Description

Labcorp offers hereditary cancer and rare disease genetic testing alongside its broader clinical lab menu, competing with Ambry for health-system and physician office volume, particularly on integrated lab contracts.

TypeBroad incumbent
Description

Quest offers hereditary cancer and pharmacogenomic testing as part of its broader diagnostic menu. It is a broad incumbent with extensive US payer relationships that overlap with Ambry's distribution, though it does not specialize in Ambry's exome + RNA niche.

TypeDirect peer
Description

GeneDx is one of Ambry's closest direct competitors, offering hereditary cancer, rare disease exome, and pediatric genetics testing through a CLIA-certified lab. The two compete head-to-head on hereditary cancer panels and exome-based diagnostics for US providers.

TypeDirect peer
Description

Natera competes with Ambry in hereditary cancer testing (Empower genetics) and oncology molecular diagnostics, with overlapping hospital and oncologist customer segments.

TypeDirect peer
Description

Veracyte is an oncology molecular diagnostics competitor with growing hereditary and somatic oncology franchises. It overlaps with Ambry in oncology genetic insights for providers and health systems.

TypeDirect peer
Description

NeoGenomics provides oncology-focused genetic and molecular testing serving community oncologists and hospitals, competing with Ambry's oncology test menu for the same provider customer base.

TypeDirect peer
Description

Myriad is a legacy leader in hereditary cancer testing (BRACAnalysis, myRisk) and competes with Ambry in hereditary cancer panels, with overlapping target customers among oncologists, breast centers, and OB/GYNs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ambry Genetics

Clinical Genetic Testingambrygen.com

Ambry Genetics is a clinical genetic diagnostics laboratory offering hereditary cancer, cardiovascular, neurological, and rare disease DNA/RNA testing through its CLIA-certified lab, serving healthcare providers, health systems, and pharmaceutical partners, and operating as a Tempus AI subsidiary.

What Ambry Genetics does

Ambry Genetics is a clinical genetic diagnostics laboratory founded in 1999 and headquartered in Aliso Viejo, California, operating a CLIA-certified, CAP-accredited 65,000 sq. ft. SuperLab that has completed more than one million DNA/RNA tests across hereditary cancer, cardiology, neurology, and rare disease. Its core technology stack combines next-generation sequencing on Illumina platforms with PacBio long-read sequencing, layered with the proprietary +RNAinsight concurrent DNA/RNA testing method that identifies additional positive patients and reduces variants of uncertain significance. Supporting products include the Classifi variant classification program, the Patient for Life proactive reanalysis program, the ExomeReveal exome test with RNA analysis, and the CARE Program digital health platform that integrates with provider EMRs for automated risk screening, ordering, and result reporting.

The business generates revenue primarily through clinical genetic testing billed to insurance, with contracts covering roughly 95% of US insured lives and most patients paying $0 out of pocket; secondary streams include pharma services (companion diagnostics development, clinical trial support, real-world data) and data licensing. The go-to-market is a hybrid model: sales-led enterprise relationships with health systems (anchored by the CARE Program), healthcare provider ordering through the AmbryPort portal and paper requisitions, and channel partnerships such as AnyLabTestNow for sample collection and sponsored testing programs (AmbryLink) with biopharma companies. In February 2025, Ambry was acquired by Tempus AI for $600 million and now operates as a wholly-owned subsidiary, with Tempus reporting 23% hereditary volume growth in Q4 2025 and Ambry contributing to over 200 peer-reviewed publications that reinforce its scientific positioning. The company faces pending litigation including an Illinois GIPA class action related to genetic data transfer during the acquisition and a securities class action against Tempus citing billing practices at Ambry.

Ambry Genetics firmographics

Firmographics
Name
Ambry Genetics
Legal name
Ambry Genetics
Website
https://ambrygen.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Ambry Genetics is a clinical genetic diagnostics laboratory offering hereditary cancer, cardiovascular, neurological, and rare disease DNA/RNA testing through its CLIA-certified lab, serving healthcare providers, health systems, and pharmaceutical partners, and operating as a Tempus AI subsidiary.
Ownership category
akta.pro rank

Ambry Genetics industry classification

Industry
Product category
Clinical Genetic Testing
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Clinical genetic testing
  • Hereditary cancer diagnostics
  • DNA RNA sequencing
  • Exome diagnostic services
  • Companion diagnostics

Where Ambry Genetics is headquartered

Location

Headquarters

HQ city
Aliso Viejo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ambry Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Genetic Testing Services: Ambry generates revenue through clinical genetic testing for hereditary cancer, cardiology, neurology, and rare diseases. Tests are billed to insurance (with majority of US health plans contracted), with 4 out of 5 patients paying $0 on average due to insurance coverage. For uninsured or those not using insurance, self-pay pricing is available.
  2. Pharma Services: Ambry provides genetic testing services to pharmaceutical companies for drug development, clinical trial support and patient identification, real-world data services, and companion diagnostics development. Supports therapeutic areas including oncology, neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases.
  3. Data Licensing: Ambry generates revenue through licensing its genetic data assets to pharmaceutical and research partners for drug discovery and development purposes. The company has contributed to research published in Nature Communications on variant effect analysis.

Pricing tiers

ModelBillingPrice
SubscriptionPer testStandard insurance-covered testing (majority of patients)
One time/ perpetual licensePay-as-you-goSelf-pay pricing for uninsured patients
HybridAnnualFinancial Assistance Program

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Ambry Genetics product offering

Product offering

Core offering

Ambry Genetics operates one of the largest clinical genetic testing laboratories in the world, providing hereditary cancer, cardiovascular, neurological, and rare disease genetic testing from a 65,000 sq. ft. CLIA-certified, CAP-accredited facility in Aliso Viejo, CA. The laboratory offers proprietary paired DNA/RNA testing (+RNAinsight), exome-based testing (ExomeReveal), the Patient for Life proactive reanalysis program, the CARE Program digital health platform, companion diagnostics development, and pharma research services.

Product overview

Ambry Genetics offers a comprehensive clinical genetic testing platform with multiple interconnected products and services. The core testing portfolio spans four main areas: Oncology (hereditary cancer panels with +RNAinsight®), Cardiology, Neurology, and Clinical Genomics (exome testing with ExomeReveal®). Key platform features include the CARE Program® for patient identification and workflow automation, Patient for Life Program™ for proactive reanalysis, Classifi® for variant classification, and AmbryPort® for online ordering. Additional services include pharma partnerships, telemedicine counseling, insurance pre-verification, and sponsored testing through AmbryLink. The company pioneered paired DNA/RNA testing with +RNAinsight® and offers the largest genetic sequencing lab in the world (SuperLab).

Differentiator

Problem solved

Functional benefit

Brands

  • +RNAinsight®: Concurrent DNA/RNA testing technology that analyzes functional RNA data to help detect and classify DNA variants, identifying more positive results and resolving variants of uncertain significance.
  • Patient for Life Program™
  • ExomeReveal®
  • CARE Program®
  • Classifi®
  • AmbryPort®
  • AmbryLink

Products and services

  • Hereditary Cancer Test Menu Clinical genetic testing panels for hereditary cancer syndromes, including BRCA1/2 testing, offered to healthcare providers for patient diagnosis, treatment planning, and risk assessment.
  • Cardiology Test Menu Hereditary cardiovascular genetic testing panels for inherited heart conditions, providing diagnostic insights for cardiomyopathies, arrhythmias, aortopathies, and familial hypercholesterolemia.
  • Neurology Test Menu Hereditary neurological genetic testing for neurodevelopmental, neuromuscular, movement, and seizure disorders, supporting diagnosis of pediatric and adult neurological conditions.
  • Clinical Genomics Test Menu Exome sequencing and rare disease testing for unresolved clinical cases, including trio-based exome testing and family variant testing to identify the genetic basis of rare conditions.
  • +RNAinsight Concurrent DNA and RNA testing add-on that analyzes both genomic and transcriptomic data to improve variant interpretation, identifying approximately 1 in 25 positive patients missed by DNA-only testing and reducing variants of uncertain significance by 6%.
  • Patient for Life Program Proactive reanalysis program that re-evaluates exome data as new scientific discoveries emerge, providing additional diagnoses for approximately 5% of initially negative patients without requiring a new sample.
  • ExomeReveal Exome sequencing combined with RNA analysis to provide enhanced diagnostic insights for rare disease cases, integrating transcriptomic data with genomic findings.
  • CARE Program Digital health solution that analyzes electronic medical record (EMR) data to identify at-risk patients who qualify for genetic testing, integrating into health system workflows to streamline patient identification, consent, and testing.
  • Pharma Services Genetic testing and genomic research services for pharmaceutical companies supporting drug development, clinical trials, real-world data generation, and data licensing initiatives.
  • Companion Diagnostics Development and validation of companion diagnostic tests to identify patients likely to respond to specific targeted therapies, supporting pharmaceutical partners in precision medicine programs.
  • AmbryLink Sponsored genetic testing programs that enable pharmaceutical and biotech companies to fund no-cost genetic testing for patients meeting specific clinical criteria.
  • Telemedicine Genetic Counseling Board-certified genetic counseling services delivered via telemedicine to support patients and providers in interpreting genetic test results and understanding implications.
  • Sample Collection Kit Delivery Direct-to-patient and direct-to-provider shipping of sample collection kits for saliva and blood samples, supporting remote specimen collection across the United States and Canada.

Quantifiable outcome

  • 1 in 25 positive patients would have been missed without RNA data (using +RNAinsight)
  • +4 more outcomes

Companies that use Ambry Genetics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Ambry Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Ambry Genetics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Child Neurology FoundationcoreStrategic or Co-development Partner · 11 March 2026Ambry Genetics named Champion Level Partner of the Child Neurology Foundation, supporting the foundation's education initiatives and resources for families and healthcare professionals in pediatric neurology. The partnership aims to advance earlier diagnosis and strengthen care through evidence-based education, diagnostics, and resources.
  • Genome MedicalcoreStrategic or Co-development PartnerPartnership with Genome Medical, a nationwide specialty medical practice focused on genetic counseling, to provide expert genetic consultations for patients who may be at risk for common hereditary cancers. Genome Medical genetic experts and primary care MDs work with patients to determine whether genetic testing is appropriate.
  • MDxHealthminorChannel Partner/ Reseller/ DistributorPartnership with MDxHealth to increase genetic testing within the urology market.
  • AnyLabTestNowminorChannel Partner/ Reseller/ DistributorPartnership with AnyLabTestNow for local laboratory sample collection services, enabling patients to visit nearby locations for blood draws.
  • PRECEDE ConsortiumcoreStrategic or Co-development PartnerPartnership with REALM IDx (parent company of Ambry Genetics) and PRECEDE Consortium to bring expertise in genetic testing, pathology, and imaging to determine who is at elevated risk for pancreatic cancer and invite high-risk individuals into state-of-the-art clinical screening programs.
  • Arrowhead PharmaceuticalscoreChannel Partner/ Reseller/ DistributorFCS Seek program - Arrowhead Pharmaceutical Program offers confidential genetic testing for patients with clinical history of severe hypertriglyceridemia, testing for underlying genetic causes like Familial Chylomicronemia Syndrome (FCS) and hyperlipoproteinemia.
  • Rocket PharmaceuticalscoreChannel Partner/ Reseller/ DistributorMission: Genome Danon Disease Genetic Testing Program - testing for patients under 40 years of age meeting select eligibility utilizing Ambry's CardioNext testing panel.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Ambry Genetics competitors and assessment

Company assessment

Direct peers

  • Caris Life Sciences: Caris is a molecular science competitor with commercial overlap with Ambry in oncology testing and an existing mutual commercial partnership. It competes for oncology hereditary and somatic testing volume.
  • GeneDx: GeneDx is one of Ambry's closest direct competitors, offering hereditary cancer, rare disease exome, and pediatric genetics testing through a CLIA-certified lab. The two compete head-to-head on hereditary cancer panels and exome-based diagnostics for US providers.
  • Natera: Natera competes with Ambry in hereditary cancer testing (Empower genetics) and oncology molecular diagnostics, with overlapping hospital and oncologist customer segments.
  • Veracyte: Veracyte is an oncology molecular diagnostics competitor with growing hereditary and somatic oncology franchises. It overlaps with Ambry in oncology genetic insights for providers and health systems.
  • NeoGenomics: NeoGenomics provides oncology-focused genetic and molecular testing serving community oncologists and hospitals, competing with Ambry's oncology test menu for the same provider customer base.
  • Myriad Genetics: Myriad is a legacy leader in hereditary cancer testing (BRACAnalysis, myRisk) and competes with Ambry in hereditary cancer panels, with overlapping target customers among oncologists, breast centers, and OB/GYNs.

Emerging players

  • Color Health: Color offers hereditary cancer and population genetic testing with a digital-first model and employer/payer channels. It overlaps with Ambry on hereditary cancer testing but differentiates through consumer/employer distribution rather than provider referrals.

Regional players

  • Centogene: Centogene focuses on rare disease diagnostics and hereditary testing primarily in Europe, the Middle East, and LatAm. It is a direct competitor in rare disease exome testing but operates in geographies where Ambry does not currently accept orders.

Broad incumbents

  • Laboratory Corporation of America (Labcorp): Labcorp offers hereditary cancer and rare disease genetic testing alongside its broader clinical lab menu, competing with Ambry for health-system and physician office volume, particularly on integrated lab contracts.
  • Quest Diagnostics: Quest offers hereditary cancer and pharmacogenomic testing as part of its broader diagnostic menu. It is a broad incumbent with extensive US payer relationships that overlap with Ambry's distribution, though it does not specialize in Ambry's exome + RNA niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Ambry Genetics social profiles

Digital presence

Ambry Genetics compliance and trust

Trust signal

Compliance7 records

Ambry Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ambry Genetics leadership team

Management profile

Number of profiles

Profiles9 records

Ambry Genetics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ambry Genetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambry Genetics

What does Ambry Genetics do?

Ambry Genetics operates one of the largest clinical genetic testing laboratories in the world, providing hereditary cancer, cardiovascular, neurological, and rare disease genetic testing from a 65,000 sq. ft. CLIA-certified, CAP-accredited facility in Aliso Viejo, CA. The laboratory offers proprietary paired DNA/RNA testing (+RNAinsight), exome-based testing (ExomeReveal), the Patient for Life proactive reanalysis program, the CARE Program digital health platform, companion diagnostics development, and pharma research services.

Is Ambry Genetics a public or private company?

Ambry Genetics is a private company. It is classified as corporate owned and is currently operating.

When was Ambry Genetics founded?

Ambry Genetics was founded in 1999. It employs 501 to 1,000 people.

Where is Ambry Genetics based?

Ambry Genetics is headquartered in Aliso Viejo, United States, in the North America region.

How does Ambry Genetics make money?

Three revenue lines are on record. Clinical Genetic Testing Services are the primary driver. The others are pharma Services and data Licensing.

Who are Ambry Genetics's main competitors?

Direct peers on record are Caris Life Sciences, GeneDx, Natera, Veracyte, NeoGenomics and Myriad Genetics. Color Health is listed as an emerging player. Centogene is listed as a regional player. Broad incumbents are Laboratory Corporation of America (Labcorp) and Quest Diagnostics.

Does Ambry Genetics have an API?

No public API is recorded for Ambry Genetics.

What industry is Ambry Genetics in?

Ambry Genetics's product category is Clinical Genetic Testing. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAmbry Genetics launches whole genome sequencing solutionAmbry Genetics, a Tempus AI subsidiary, launched GenomeNext and GenomeReveal, whole genome sequencing products for rare disease diagnosis. The offering combines sequencing with RNA analysis and ongoing reanalysis, citing data that RNA analysis can increase diagnostic yield. The company also cites its reanalysis program leading to positive reclassifications in 5% of previously negative or uncertain cases.The future of tradingTempus AI unit Ambry Genetics launches GenomeNext whole-genome sequencing test for rare diseasesAmbry Genetics, a Tempus AI subsidiary, launched GenomeNext, a whole-genome sequencing test for rare-disease diagnosis. The test uses a pangenome reference to improve variant detection across diverse ancestral backgrounds, and GenomeReveal adds integrated RNA analysis. Ambry's Patient for Life program includes laboratory-initiated reanalysis, citing 5% positive reclassifications from prior negative or uncertain cases.Stock TitanAmbry Genetics launches whole-genome sequencing testAmbry Genetics, a Tempus AI subsidiary, launched GenomeNext and GenomeReveal, a whole-genome sequencing solution for rare disease diagnosis. The test combines pangenome reference, RNA analysis, and ongoing reanalysis, with published data showing RNA analysis increases diagnostic yield and reanalysis yields positive reclassifications in 5% of prior negative or uncertain cases.Business Wire BlogAmbry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare DiseasesAmbry Genetics launched GenomeNext and GenomeReveal, a whole genome sequencing solution for rare disease diagnosis. The approach uses a pangenome reference and integrated RNA analysis, with laboratory-driven reanalysis reclassifying 5% of previously negative or uncertain cases.YahooAmbry Genetics Launches Whole Genome Sequencing Tests to Improve Rare Disease DiagnosisAmbry Genetics launched GenomeNext and GenomeReveal, whole genome sequencing tests for rare disease diagnosis, combining DNA sequencing, RNA analysis, and ongoing reassessment. The tests use a pangenome reference to improve variant detection across diverse populations, with reanalysis of previously negative cases in 5% of cases. Pricing and volumes were not disclosed.PR NewswireCancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™The cancer tumor profiling market is projected to grow from $12.02 billion in 2026 to $19.87 billion by 2031, a CAGR of 10.6%. North America held the largest regional share in 2025, while Asia Pacific is expected to see the fastest growth at 12.8%. M&A activity is focused on MRD, AI pathology, and liquid biopsy platforms.ZacksTEM's Diagnostics Arm Expanding Rapidly: What's Driving the Growth?Tempus AI's diagnostics segment experienced strong growth in 2025, driven by the adoption of precision oncology and minimal residual disease (MRD) testing. The company expanded its capabilities through the acquisition of Ambry Genetics and the integration of artificial intelligence tools like Paige Predict. Meanwhile, competitors Illumina and Guardant Health also advanced their genomics and liquid biopsy portfolios to meet rising clinical demand.Venture Capital Access OnlineBios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and SurveillanceBios Life emerged from stealth with $25M in seed financing led by Redmile, Vsquared Ventures, and Kindred Capital. The company will partner with Tempus to train predictive models for cancer surveillance, targeting high-risk individuals and survivors. The platform launches in the US in the second half of 2026.News-MedicalPhelan-McDermid syndrome may be more common than previously believedNew research from Mount Sinai's Seaver Autism Center, published June 28 in Autism Research, has estimated that Phelan-McDermid syndrome affects approximately 1 in 7,300 people, dramatically higher than previous estimates. The study analyzed genetic data from nearly 180,000 individuals with autism across ten independent sources including GeneDx, Labcorp, and Ambry Genetics, projecting that over 45,000 people in the United States may be living with the condition. Researchers recommend universal genetic testing for children with autism to enable access to emerging precision medicine therapies and clinical trials.Mirage NewsAutism Study: Phelan-McDermid Affects 1 in 7,300New research led by scientists from the Seaver Autism Center at Mount Sinai, published June 28 in Autism Research, has estimated that Phelan-McDermid syndrome affects approximately 1 in 7,300 people, dramatically higher than previous estimates. The study analyzed genetic data from nearly 180,000 individuals with autism across ten independent sources including GeneDx, Labcorp, Ambry Genetics, and the SPARK research study. The findings indicate that more than 45,000 people in the United States may be living with the condition, supporting recommendations for universal genetic testing in autism cases.